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 Summary 
 
Title: Secondary Hyperparathyroidism: Update on pathogenesis, diagnosis and 
treatment 
 
Author: Stipe Ivancic 
 
Secondary hyperparathyroidism is a frequently encountered problem in the 
management of patients with chronic kidney disease (CKD). Its pathophysiology is 
mainly due to hyperphosphatemia, vitamin D deficiency and resistance.  Resistance in 
the form of downregulation in parathyroid vitamin D and calcium-sensing receptors 
represent critical steps in pathogenesis.  Eventually abnormalities in mineral phosphate, 
calcium, and vitamin D begin to appear. Lack of control of serum PTH and associated 
minerals result in bone pathologies and vascular calcification. This condition has a high 
impact on the mortality and morbidity of dialysis patients.  Early diagnosis of secondary 
hyperparathyroidism is crucial in the management of patients with CKD.  Achieving 
current targets for the key mineral parameters in the management of SHPT set by the 
Kidney Disease Improving Global Outcomes (KDIGO) guidelines can be challenging. 
This review summarizes the current understanding and evidence supporting strategies 
for SHPT treatment in CKD patients. Treatment should include a combination of dietary 
phosphorus restriction, phosphate binders, vitamin D sterols, and calcimimetics. 
Parathyroidectomy is effective in suitable candidates’ refractory to medical therapy and 
the standard against which new approaches should be measured.  
 
Key Words: Chronic Kidney Disease-Mineral Bone Disorder, Vascular Calcification, 
FGF 23, PTH, Bone Biopsy, Calcimimetics, Phosphate Binders, Calcitriol, Paricalcitol 
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Introduction 
 
Secondary hyperparathyroidism is a maladaptive response that occurs as a result of 
declining kidney function.  Though this response is adaptive in the early stages, 
prolonged stimulus leads to several pathologies involving extra skeletal calcification, 
several possible bone disorders and finally derangements in PTH, phosphate, calcium 
and vitamin D serum levels.  These disorders are labeled under the term CKD-MBD, to 
replace the previous term of renal osteodystrophy, which focused primarily on CKD 
related bone pathologies. Skeletal changes that take place in CKD increase the 
prevalence of hip fracture compared to general population in stages of CKD including 
dialysis.  Dialysis patients in their 40s have a relative risk of hip fractures 80-fold that of 
age- and sex-matched controls (Alem et al. 2000).  Cardiovascular disease accounts for 
70% of all deaths in patients with CKD, with an overall mortality of 20% per year in 
patients with dialysis (USRDS et al. 2003).  In individuals with kidney failure on dialysis, 
cardiovascular mortality rates are 10-500-times higher than in the general population, 
even after adjustment for gender, race and the presence of diabetes (Foley et al. 1998).  
One mechanism by which abnormal mineral metabolism may increase cardiovascular 
risk is by inducing or accelerating arterial calcification. A substantial body of 
observational data has now established components of disordered mineral metabolism 
as independent risk factors for adverse outcomes in CKD patients.  These include 
serum levels of phosphate, PTH and FGF-23.  With all of these derangements there 
seems to be an increase in morbidity and mortality in patients with CKD. 
 
Pathogenesis of Secondary Hyperparathyroidism 
 
Physiology of Calcium and Phosphorus Homeostasis 
 
Parathyroid Hormone 
 
PTH acts mainly on two organs: the bone and the kidney. The immediate effect of PTH 
on bone is to mobilize calcium from skeletal stores that are readily available and in   
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equilibrium with the extracellular fluid (Talmage & Mobley 2008). Later effects on bone 
include, PTH activation of bone resorption to further increase calcium (Talmage & 
Mobley 2008).  Renal effects include: calcium reabsorption in the ascending loop of 
Henle and distal convoluted tubule (Van Abel et al. 2005).  Phosphate reabsorption 
under PTH occurs in the proximal tubule (Pfister et al.1997). This effect is primarily 
mediated by decreased activity, internalization, and degradation of the sodium-
phosphate cotransporter in the luminal membrane of the proximal tubules (Pfister et 
al.1997).  Finally, PTH stimulates the synthesis of 1-alpha hydroxylase in the proximal 
tubules and thus converts calcidiol to calcitriol (Broadus et al. 1980). Calcium has a 
negative feedback effect on the parathyroid glands through the calcium sensitizing 
receptor.  Phosphate has shown to have a direct stimulatory effect on parathyroid gland 
hormone secretion (Brown & Hebert 1997). 
 
Vitamin D 
 
The active form of Vitamin D (1, 25 dihydroxyvitamin D) is synthesized in the kidney by 
the enzyme 1-alpha hydroxylase.  Vitamin D stimulates reabsorption intestinal calcium 
and phosphate.  Along with PTH, vitamin D is a required factor for in the bone 
reabsorption.  It also increases the reabsorption of urinary calcium and phosphorus in 
the renal tubules.  Through the vitamin D receptors it has a direct effect on the 
parathyroid glands to supress PTH secretion (Ben-Dov et al. 2007).  
 
Fibroblast Growth Factor- 23 
 
FGF-23 is a circulating peptide that plays a key role in the control of serum phosphate 
concentrations (Llach 1995). FGF-23 is secreted by bone osteocytes and osteoblasts in 
response to calcitriol, increased dietary phosphate load, PTH, and calcium (Llach 1995).  
FGF-23's primary function is to maintain normal serum phosphate concentration by 
reducing renal phosphate reabsorption and by reducing intestinal phosphate absorption 
through decreased calcitriol production (Llach 1995). FGF-23 also suppresses PTH 
secretion by the parathyroid gland (Llach 1995). 
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Calcium and Phosphorus Metabolism in Renal Failure 
 
Hyperphosphatemia  
 
The subclinical hyperphosphatemia that occurs at estimated GFR’s of >30 mL/min, is 
said to be the principal factor leading to the development of secondary 
hyperparathyroidism (Llach 1995). As GFR decreases so does the filtered phosphate 
load.  The initial increases in phosphate promote the following: 
 
1. The induction of hypocalcaemia by serum phosphate and serum ionized calcium 
binding (leading to increase PTH synthesis)  
2. Decreased formation/activity of calcitriol by direct effects of phosphate at the enzyme 
level (leads to a decrease in phosphate and calcium absorption in the intestines)  
3. Increased PTH gene expression (leading to increase PTH secretion)  
4. Increased secretion of FGF-23 (Llach 1995) 
 
From the viewpoint of phosphate homeostasis, the initial elevation in PTH secretion as 
result of high phosphate is appropriate since the ensuing increase in phosphate 
excretion lowers the plasma phosphate concentration toward normal. Among patients 
with severely reduced GFR, PTH inhibits proximal tubule phosphate reabsorption from 
the normal 80 to 95 percent to as low as 15 percent of the filtered phosphate (Gutierrez 
et al. 2005). Hyperparathyroidism also tends to correct both the hypocalcemia (by 
increasing bone resorption) and the calcitriol deficiency (by stimulating the 1-
hydroxylation of calcidiol (25-hydroxyvitamin D) (Gutierrez et al. 2005). However, as 
GFR further decreases, filtered phosphate cannot be excreted and more phosphate is 
mobilized from bone (Gutierrez et al. 2005). PTH and FGF-23 help maintain normo-
phosphatemia until the GFR reaches 20 ml/min (Gutierrez et al. 2005). 
 
To make the situation even more complicated hyperphosphatemia also stimulates the 
secretion of FGF-23, which acts to suppress PTH secretion and vitamin D synthesis 
(Gutierrez et al. 2005). FGF-23 molecule synthesis increases at an early stage even 
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without hyperphosphatemia contributing to the possibility of the revised trade off 
hypothesis (Rodriguez et al. 2005) (Figure 1). Early target in treatment of secondary 
hyperparathyroidism revolves on the reduction of phosphate load and reduces 
mechanisms of the revised trade off hypothesis. 
 
 
Calcitriol Involvement 
 
The initial decline in calcitriol synthesis is most likely affected by the increased secretion 
of FGF-23 by the osteoblasts (the revised trade-off hypothesis) (Fukagawa et al. 2013).  
This is especially prominent at early stages of chronic renal failure.  Other mechanisms 
such as hyperphosphatemia reduce calcitriol synthesis during later stages of renal 
failure.  The FGF-23 has a direct inhibitory effect on the renal 1-alpha hydroxylase. Low 
Figure 1. Role of FGF23 in the revised 
trade-off theory on pathogenesis of 
secondary hyperparathyroidism, according 
to: Fukagawa (2013), p 866, from Expert 
Opinion Pharmacotherapy.  The reverse 
trade off hypothesis is the following: dietary 
phosphorus load supresses activation of 
vitamin D within the kidney.  FGF-23 is 
synthesized to reduce serum phosphorus 
and inhibit vitamin D synthesis.  These two 
mechanisms stimulate PTH secretion. 
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calcitriol concentrations increases PTH secretion by indirect and direct mechanisms.  
Indirect effects on PTH are achieved through decreased intestinal absorption of calcium 
and calcium release from bone, both of which promote the development of 
hypocalcaemia, which stimulates PTH secretion.  Direct mechanisms result from the 
loss of inhibitory affects at the level of VDR receptors on parathyroid glands (Gogusev 
et al. 1997). Low calcitriol concentrations appear to play an important role in the decline 
in VDRs since the defect can be largely corrected by calcitriol supplementation 
(Gogusev et al. 1997).  Calcitriol is given to increase the number of VDR’s to sensitize 
the parathyroid gland for further release of parathyroid hormone (Gogusev et al. 1997). 
 
Hypocalcaemia and Calcium Sensitizing Receptors (CaSR) 
 
The release of PTH from parathyroid glands in response to low concentration of calcium 
is regulated by the CaSR (Naveh-Many et al. 1995).  In CKD, the number of CaSRs 
may be reduced in hypertrophied parathyroid glands, particularly in areas of nodular 
hypertrophy (Naveh-Many et al. 1995).  Decreased expression of the CaSR appears to 
be related to the proliferation of parathyroid tissue, and both may be related to 
increased phosphorus (Naveh-Many et al. 1995).  The change in receptor number can 
lead to inadequate suppression of PTH secretion by calcium, resulting in inappropriately 
high PTH concentrations in the setting of normal or high calcium concentrations (Naveh-
Many et al. 1995).  Total serum calcium concentration are low during CKD as a result of 
all of the aforementioned mechanisms.  This low serum calcium can be considered to 
be a stimulus to increase in PTH secretion (Naveh-Many et al. 1995). The role of the 
CaSR in regulating parathyroid gland function has direct therapeutic implications. The 
administration of a calcimimetic agent increases the sensitivity of the receptor to 
extracellular calcium and can lower PTH secretion from the parathyroid gland (KDIGO et 
al. 2009). 
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Skeletal resistance to PTH  
 
Skeletal resistance to the calcemic action of PTH appears to contribute to the genesis of 
secondary hyperparathyroidism in CKD.  Resistance to PTH is primarily due to down 
regulation of PTH receptors induced by the high circulating PTH concentrations, 
although both calcitriol deficiency and hyperphosphatemia may play a contributory role 
(Isakova et al. 2011). 
 
Parathyroid Hyperplasia  
Prolonged stimulation of PTH secretion leads initially to diffuse polyclonal hyperplasia 
followed by monoclonal nodular hyperplasia (Tominaga & Takagi 1996) (Figure 2).  
These two process ultimately lead to tertiary hyperparathyroidism where PTH is 
autonomously secreted, that is unresponsive to serum calcium levels (Tominaga & 
Takagi 1996). Furthermore therapies such as calcimimetic and vitamin d analogs do not 
reduce the levels of PTH (Drueke et al. 2007). Potential pathogenic factors include 
down regulation of VDR and CaSR receptors (Tominaga & Takagi 1996).  As 
monoclonal nodular hyperplasia develops, it continues overgrow into an adenoma, 
further increasing PTH secretion (Tominaga & Takagi 1996). Often these patients 
require parathyroidectomy’s to control calcium-phosphate homeostasis (Tominaga and 
Takagi 1996).  
 
Figure 2. Development of parathyroid hyperplasia, according to: Tominaga (1996), p 339, from 
Current Opinion Nephrology Hypertension. 
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Vascular Calcification 
 
The initial step in the development of vascular calcification is the de-differentiation of 
vascular smooth muscle cells to osteo/chondrogenic-like cells by transcription factors 
such as Runx2 and Msx2 (Figure 3) (Moe & Chen 2008). These cells can then form 
matrix vesicles or apoptotic bodies that mineralize on an extracellular matrix, 
presumably in a manner similar to bone (Moe & Chen 2008).  Cells form collagen and 
non-collagenous proteins in the intima or media and incorporate calcium and 
phosphorous into matrix vesicles to initiate mineralization and further grow the mineral 
into hydroxyapatite (Moe & Chen 2008). The existence of abnormal bone remodelling in 
CKD may accelerate the process by providing excess calcium and phosphate for matrix 
vesicles (Moe & Chen 2008).  The overall pathogenesis is regulated by a balance of 
pro-calcifying factors and inhibitors (Moe & Chen 2008).  Unfortunately in CKD, the 
procacifying factors including hyperphosphatemia and hyperparathyroidism are 
common, and inhibitors such as fetuin-A and matrix gla protein are reduced (Moe & 
Chen 2008). 
 
Figure 3. Pathogenesis of vascular calcification according to: Moe (2008), p 215, from Journal of 
the American Society of Nephrology. 
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Diagnosis of Secondary Hyperparathyroidism 
 
Diagnosing Bone Pathologies 
 
Overview 
 
Several bone pathologies can occur in patients with CKD (Figure 4).  These include the 
following: 
1. Predominant hyperparathyroid-mediated high-turnover bone disease 
2. Low-turnover osteomalacia  
3. Mixed uremic osteodystrophy  
4. Osteomalacia  
5. Adynamic bone disease 
6. Aluminum deposition bone pathologies (Torres et al. 2014) 
 
 
Figure 4. Different bone pathologies according to: Torres (2014), p 615, from Seminars in 
Nephrology.  Column 1 shows typical severe secondary hyperparathyroidism with high bone 
turnover, volume, and mineralization.  Column 2 denotes the case of secondary 
hyperparathyroidism with low bone volume, normal mineralization, and high bone turnover.  
Column 3 shows the case of adynamic bone disease with all 3 TMV parameters reduced.  
Column 4 describes the usual osteomalacia with low bone turnover, low mineralization, but 
normal bone volume. Columns 5 and 6 show2 situations of mixed osteodystrophy; In column 5 
bone volume is high, turnover is low, and mineralization is normal; in column 6 bone volume is 
low, turnover is normal, and mineralization is reduced. 
9 
 
 
Bones are evaluated by three parameters: turnover, mineralization, and volume (TMV 
classification). Each form of bone disease has its own characteristic histologic findings. 
Regardless of the type of bone disease, fracture risk in CKD patients is 14 to 17 greater 
than normal controls (Coco & Rush 2000). 
 
Role of PTH 
 
PTH is used as marker for severity of hyperparathyroidism.  It cannot predict the 
underlying bone disease particularly PTH levels in the moderate range (KDIGO et al. 
2009).  PTH ranges for prediction of underlying bone disease include the following: 
Intact serum PTH values <100 pg/mL are associated with a decreased likelihood of 
osteitis fibrosa (OF) and an increased incidence of adynamic bone disease, An intact 
serum PTH level >450 pg/mL is typically associated with hyperparathyroid bone disease 
and/or mixed uremic osteodystrophy (MUO) and Intermediate PTH levels between 100 
and 450 pg/mL do not correlate well in predicting certain bone disease (KDIGO et al. 
2009). 
 
Values mentioned previously have used intact assays for PTH measurement. There 
have been second and third generational assays in clinical use.  Unfortunately present 
clinical data is based on intact assays (KDIGO et al. 2009). KDIGO guidelines suggest 
use of caution when using second or third generational assays (KDIGO et al. 2009). 
Intact PTH assay use a capture antibody against the C-terminal part of the PTH 
molecule (epitopes 39-84) and a radioiodinated detection antibody directed towards the 
N-terminal portion of PTH (epitopes 13-34), and therefore detects the intact as well as 
large C-terminal fragments that lack portions of the N-terminus (that is the first 12 
amino) and are termed non-PTH(1-84) (Figure 5) (John et al. 1999). Non-PTH(1-84) 
fragments are a subset of large C-terminal fragments that lack only a small portion of 
the N-terminus, and are therefore measured by the intact PTH assay (John et al. 1999). 
They differ from other C-terminal fragments that lack a large portion of the N-terminus 
and are not detected by the intact PTH assay (John et al. 1999). In individuals with 
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normal renal function, non-PTH(1-84) fragments account for 10 percent of all C-terminal 
PTH fragments and for 20 percent of the PTH detected by the intact PTH assay 
(Lepage et al 1998). In patients with chronic kidney disease, such as in patients on 
hemodialysis, non-PTH(1-84) may account for as much as 45 percent of the 
immunoreactivity measured by the intact PTH assay (Block et al. 2004).  
Bioactive assays use antibodies directed at epitopes located at N terminal ends as well 
as C terminal ends bypassing non-PTH fragments detected by first generational assays.  
bioactive PTH assay reacted with PTH(1-84) and with another N-terminal PTH 
fragment, which is not recognized by the intact PTH assays (Figure 5) (D'Amour et al. 
2003). In individuals with normal renal function, N-PTH accounts for 4 to 8 percent of 
PTH detected with a bioactive PTH assay, whereas it accounts for up to 15 percent in 
patients with renal failure (D'Amour et al. 2003). To further add, there is excellent 
correlation between intact and bioactive assays.  Mean PTH levels in intact assays are 
larger due to detection of large c-fragments (non-PTH 1-84) mentioned above (D'Amour 
et al. 2003). 
 
Figure 5. Schematic presentation of PTH(1-84) and the approximate location of the peptide 
regions recognized by the antibodies used in displacement-type radioimmunoassays and in 
"two-site" immunometric assays according to Heinrich (2006), p 54 from Clinical Chemistry. 
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Oxidized PTH occurs in patients with chronic kidney disease due to extensive oxidative 
stress (Hocher et al. 2012).  Oxidized PTH forms the majority of PTH within these 
patients (Hocher et al. 2012).  It’s an inactive product and has no effect on the PTH 
receptor (Hocher et al. 2012). Assays used in these patients particular the intact and 
bioactive assays detect both oxidized and non-oxidized forms of PTH (Hocher et al. 
2012).  Intact and bioactive PTH assays detect both oxidized and non-oxidized PTH, 
resulting in higher PTH levels than when measured with a non-oxidized PTH assay 
(Hocher et al. 2012). At this point the non-oxidized assay may be useful in those 
patients requiring dialysis. 
 
Role of Alkaline Phosphatase 
 
Markers of osteoblast–mediated bone formation, such as bone-specific or total alkaline 
phosphatase, may provide useful information if used in conjunction with PTH serum 
levels. The combination of a low serum bone-specific alkaline phosphatase 
concentration (≤7 ng/mL) and a low serum PTH is suggestive of a low remodeling 
disorder (Ureña & De Vernejoul 1999). An elevated serum bone-specific alkaline 
phosphatase (≥20 ng/mL), alone or in combination with increased serum PTH (>200 
pg/mL), appears to be highly sensitive and specific for high turnover bone disease 
(Ureña et al. 1996).  In Croatia the usage of alkaline phosphatase and PTH levels is 
sufficient in assessing metabolic bone disease.  It is worth mentioning that use of bone 
metabolic markers in conjunction with PTH or individually to asses’ high or low turnover 
states still lacks sensitivity and specificity (Ureña et al. 1996). 
 
Imaging Techniques 
 
Radiographic examination includes possible detection of subperiosteal absorption on 
plain radiographs (KDIGO et al. 2012). These changes are associated with progressive 
hyperparathyroidism (KDIGO et al. 2012). These techniques are less sensitive than 
PTH and alkaline phosphatase (KDIGO et al. 2012).  As a result routine x-rays are only 
done when there is symptomatic bone disease (KDIGO et al. 2012).  Bone mineral 
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density has limited use in CKD patients in assessing bone disease.  2012 KDIGO 
guidelines, suggest not performing BMD measurements among patients with an 
estimated glomerular filtration rate (eGFR) <45 mL/min per 1.73 m2 since information 
may be misleading or unhelpful (KDIGO et al. 2012).  
 
Bone Biopsy 
 
Bone biopsy remains the gold standard for diagnosis of symptomatic bone disease.  As 
mentioned previously, even though there is good correlation between PTH and bone 
formation rate, it cannot consistently replace bone histology because normal or even 
low bone turnover often are seen in a wide range of PTH values (2-9 fold upper normal 
limit for the assay) (Barreto et al. 2008). However in clinical practice the procedure has 
significant limitations.  Some of the issues are as follows: individual variation in uremic 
patient’s leads to false results; length of time for preparation of the procedure; the 
invasive nature of the procedure and finally financial cost.  To conclude, bone biopsies 
are not routinely done in Croatia.  In hospitals where it’s possible to perform the 
procedure, KDIGO has published guidelines for usage of bone biopsies.  Guidelines 
state: 
1. Unexplained fractures, unexplained hypercalcemia, and/or unexplained 
hypophosphatemia 
2. Persistent bone pain 
3. Possible aluminum toxicity 
4. Before therapy with bisphosphonates (KDIGO et al. 2009) 
 
Indications for bone biopsy can be further divided into Clinical, Laboratory, Radiologic 
and Research categories (Figure 6). 
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Figure 6. Indications for bone biopsy according to: Torres (2014), p 618, from Seminars in 
Nephrology. 
 
Vascular Calcification 
 
VC is most often detected incidentally on imaging obtained for other purposes (KDIGO 
et al. 2009). Screening is not attempted to quantify VC in all CKD patients since no 
specific therapy is available beyond careful attention to calcium and phosphate balance 
(KDIGO et al. 2009). This is in agreement with the 2009 Kidney Disease: Improving 
Global Outcomes (KDIGO) guidelines (KDIGO et al. 2009).  CT scanning can detect 
and quantify the level of calcium with CAC scoring (KDIGO et al. 2009).  
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Treatment of Secondary Hyperparathyroidism 
 
Treatment in Predialysis Patients 
 
The treatment of secondary hyperparathyroidism in CKD differs between different 
stages of chronic kidney disease. Clinicians should first divide patients according to the 
severity of kidney disease before deciding on treatment decisions (Figure 7). Recent 
observational data and multiple clinical trials have shown different clinical outcomes 
regarding therapy in these two groups of patients. Furthermore patients in the 
predialysis group still have clinically significant working kidneys.  As a result similar 
therapies used in both groups might produce different outcomes.  More clinical trials are 
required to asses’ efficacies of treatment in regards to phosphate binders and vitamin D 
analogs. There is still ongoing debate in the nephrology community as to what the 
correct approach is to these patients.  
 
Figure 7.  Staging of kidney disease according to: National Kidney Foundation (2003) from the 
National Kidney Foundation. 
 
Treatment goals in regards to laboratory values of serum phosphate, calcium and PTH 
should be tailored to the KDIGO guidelines. The KDIGO guidelines recommend using 
intact PTH levels to evaluate and manage bone abnormalities (KDIGO et al. 2012). 
KDIGO suggests initiating therapy when the serum PTH is progressively rising and 
remains persistently above the upper limit of normal for the assay (KDIGO et al. 2012). 
The clinician is required to be aware of the particular assay and normal values 
associated with its use (KDIGO et al. 2012).  With respect to calcium and phosphate 
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levels, the KDIGO working group suggests maintaining serum calcium and phosphorus 
in the normal range (ie serum phosphorus level (<4.5 mg/dL [1.45 mmol/L]) (KDIGO et 
al. 2012).  Clinicians should focus on trends rather than single laboratory values 
(KDIGO et al. 2012). 
 
Treatment algorithm is the following: 
 
Step 1- Limiting dietary phosphorus regardless of normal serum phosphate levels is 
essential in the beginning of treatment and throughout the course of the disease.  
Patients often have subclinical hyperphosphatemia that is compensated by the 
increased levels of FGF-23.  Reducing phosphorous from the diet can decrease the 
phosphate load and improve treatment outcomes.  The recommended dietary 
phosphorous intake is 900mg/day (KDIGO et al. 2012). Dietary phosphorus should be 
derived from sources of high biologic value, such as meats and eggs (KDIGO et al. 
2012). Phosphorus from food additives should also be estimated and restricted (KDIGO 
et al. 2012). Food additives (as are found in processed foods) are an important source 
of dietary phosphate. In addition to having a high phosphate content, highly processed 
food provides a more easily absorbed form of phosphate, compared with fresh, 
unprocessed foods (KDIGO et al. 2012).  
 
Step 2- After two to four months of limiting dietary phosphorous, if PTH levels persist 
the next step is to introduce phosphate binders.  Phosphate binders include calcium and 
non-calcium containing compounds. Calcium-containing phosphate binders should be 
used in patients who are hypocalcemic and normocalcemic, particularly if they are not 
also receive active vitamid D analogs. Vitamin D analogs used together with calcium 
containing phosphate binders can cause both hypercalcemia and hypophosphatemia 
with vascular calcification as a consequence.  Non-calcium-containing phosphate 
binders are used for hypercalcemic patients. They are also appropriate in 
normocalcemic CKD patients, particularly if they are also receiving active vitamin D or 
vitamin D analogs.  Non-calcium-containing phosphate binders are also used for 
patients with adynamic bone disease and vascular calcification. Calcium containing 
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binders include calcium carbonate (25% elemental calcium: 169 mg of calcium/667-mg 
capsule) and calcium acetate (40% elemental calcium: 200 mg of elemental 
calcium/500 mg of calcium carbonate) (Mia et al. 1989).  Calcium acetate is considered 
to be a more efficient phosphate binder than calcium carbonate (Mia et al. 1989).  In 
Croatia, calcium carbonate and magnesium hydroxide are widely used options. No 
studies have examined calcium-based binders versus placebo or compared the 2 forms 
of calcium-based binders with extraskeletal calcification or patient-centered outcomes, 
such as mortality, fractures, and hospitalizations.  Clinicians need to be aware of the 
effects of calcium compounds and active vitamin D compounds used together.  
Simultaneous use of both can lead to hypercalcemia and hyperphosphatemia. Also a 
note for clinicians using calcium phosphate binders: Consider the level of calcium intake 
when prescribing calcium phosphate binders; likely exceeds the 1500 mg/day limit in 
end-stage renal disease ESRD patients (NFK et al. 2003). Non calcium containing 
compounds include sevelamer hydrochloride.  Sevelamer hydrochloride is the only 
available non calcium containing phosphate binder available in Croatia. Sevelamer 
hydrochloride are nonabsorbable cationic polymers that bind phosphate through ion 
exchange.  Conventional dosing is three times daily but recently less frequent dosing 
has been used.  Side effects include GI intolerance and metabolic acidosis. A decrease 
in LDL cholesterol has been associated with its use. 
 
When comparing both calcium and non-calcium phosphate binders, non-calcium 
phosphate binders seem to be more effective.  The best available data is from a meta-
analysis of 11 open-label, randomized trials (4622 patients), which revealed a 22 
percent decrease in all-cause mortality among patients randomly assigned to receive 
noncalcium-based binders (sevelamer, 10 studies including 3268 patients, or 
lanthanum, one study including 1354 patients), compared with calcium-based binders 
(relative risk [RR] 0.78, 95% CI 0.61-0.98) (Jamal et al. 2013). Analysis of three 
nonrandomized trials (2813 patients) revealed an 11 percent reduction in mortality and, 
in all trials together, a 13 percent reduction in mortality among patients taking non 
calcium phosphate binders. Analysis of dialysis and nondialysis CKD patients showed 
similar reductions in mortality (Jamal et al. 2013).  Calcium containing phosphate 
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binders are also associated with hypercalcemia, adynamic bone disease, vascular 
calcification, and a positive calcium balance, all which could result in increased 
morbidity (Jamal et al. 2013).  Thus it’s prudent to take this factors in consideration 
when deciding on the type of phosphate binder. 
 
Step 3- If PTH levels further increase or remain elevated over a six-month period with 
optimal therapy from the previous steps, introduction of a Vitamin D derivative is the 
next essential step in management.  Treatment should not be initiated with Vitamin D 
derivatives if either serum calcium or serum phosphorous is elevated.  Under a general 
rule a Vitamin D derivative can only be introduced if the corrected serum total calcium 
concentration is <9.5 mg/dL (<2.37 mmol/L). If the serum level of corrected total calcium 
exceeds 10.2 mg/dL (2.54 mmol/L) all Vitamin D therapy should be discontinued. 
Vitamin D therapy should also be discontinued if intact PTH levels become persistently 
low. 
 
There are several divisions of Vitamin D derivatives.  There is the naturally occurring 
Vitamin D derivative calcitriol, and synthetic Vitamin D analogs paricalcitol and 
doxecalciferol.  We shall discuss calcitriol and paricalcitol as these are the only 
available Vitamin D derivatives available in Croatia.  Four placebo-controlled RCTs of 
various vitamin D analogues all showed efficacy for PTH lowering compared with 
placebo (Slatopolsky et al. 1992).  No RCTs using vitamin D analogues in this group of 
patients address key patient-level outcomes (such as mortality, fractures, quality of life 
etc.). As a result any Vitamin D derivative can be used in treatment of these patients 
In regards to paricalcitol it has been examined in one randomized trial.  In this  phase-III 
trial of 220 patients with stage 3 and 4 CKD, compared with placebo, paricalcitol 
resulted in a significant percentage of patients with at least two consecutive decreases 
in PTH levels of ≥30 percent (91 versus 13 percent) (Coyne et al. 2006). Both groups 
had similar incidences of hypercalcemia, hyperphosphatemia, and elevated calcium-
phosphorus products (Coyne et al. 2006). 
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Step 4- When all previous therapies fail in control of PTH, cinacalcet be used in 
treatment.  It is still controversial because of the lack of evidence.  In fact the (KDIGO) 
working group recommend not giving cinacalcet, given the paucity of data concerning 
efficacy and safety in predialysis patients with CKD (KDIGO et al. 2009).  Patients in 
this category of treatment can be managed by other therapeutic interventions such as 
parathroidectomy. There are risks of hypocalcemia and elevations of serum phosphate 
in its use.  If electrolyte disbalance does occur during treatment, other therapies might 
have to be adjusted such as Vitamin D derivatives, phosphate binders etc. 
Two trials have evaluated cincalcet in this category of patients. The first trial, a A phase-
II, 18-week study was performed in which 54 patients were randomly assigned to 
cinacalcet or placebo, with the dose titrated from 30 to 180 mg/day to obtain a ≥30 
percent reduction in PTH levels (Charytan et al. 2005). Inclusion criteria included GFRs 
between 15 to 50 mL/min per 1.73 m2, one intact PTH level >130 pg/mL, and a serum 
calcium concentration of 9.0 mg/dL (2.25 mmol/L) (Charytan et al. 2005). Compared 
with placebo, cinacalcet significantly lowered intact PTH levels (32 percent decrease 
versus 5 percent increase with placebo) and achieved target reduction in PTH levels (56 
versus 19 percent attained a 30 percent reduction from baseline) (Charytan et al. 2005). 
Increments in serum phosphate levels were observed with cinacalcet, which was likely 
due to the reduction in PTH levels (Charytan et al. 2005). The second trial was a A long-
term, randomized, double-blind, placebo-controlled trial of cinacalcet in 404 patients 
with stages 3 and 4 CKD reported that active therapy reduced the mean PTH level by 
43 percent after 32 weeks of treatment, but also led to an 9 percent decrease in serum 
calcium level, a 21 percent increase in serum phosphorus level, and a 14 percent 
decrease in urinary phosphorus excretion (Chonchol et al. 2009). In addition, cinacalcet 
induced a >50 percent increase in calcium excretion from baseline (Chonchol et al. 
2009). 
 
Treatment in Dialysis Patients 
 
Goals of therapy in this group of patients are slightly different than in those in the 
predialysis group mentioned above.  There is some debate as to which guideline should 
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be used to treat these patients.  The new KDIGO guidelines recommend that PTH 
levels should be 2-9 times the upper limit of normal as is defined by the specific assay.  
Previous guidelines had specific values in which PTH should be controlled.  However 
these guidelines were based on secondary generation assays that is no longer 
available. Furthermore there are data suggesting significant variability with PTH results 
among the different available assays, as well as marked differences based on sample 
collection and storage.  The KDIGO guidelines also state that calcium and phosphorous 
levels should be in the normal range.  However what is considered to be the normal 
range?  For example increased phosphorous levels have been associated with 
increases in all-cause mortality in certain prospective studies. This was best shown in a 
meta-analysis of 12 studies that included 92,345 patients with CKD, over 97 percent of 
whom were on dialysis (Palmer et al. 2011). Among 10 studies that were perceived to 
be adequately adjusted (in which seven studies were of dialysis patients), serum 
phosphate >5.5 mg/dL (1.78 mmol/L) was associated with increased mortality (Palmer 
et al. 2011) The KDIGO guidelines are not specific enough for this recommendation.  
Based on the previously mentioned statements the following should be the standard 
goals of therapy: 
 
1. PTH levels should be 2-9 times the upper limit of normal as is defined by the specific 
assay. (KDIGO et al. 2009) 
2. Serum levels of phosphorus should be maintained between 3.5 and 5.5 mg/dL. (NFK 
et al. 2003) 
3. Serum levels of corrected total calcium should be maintained between 8.4 and 9.5 
mg/dL. (NFK et al. 2003) 
 
The approach to treatment consists of the following: the initial focus is managing 
secondary hyperparathyroidism is the management of hyperphosphatemia with diet 
and/or phosphate binders. Specific interventions are based upon serum phosphate and 
calcium levels. The next step is to decide whether phosphate binder therapy is sufficient 
or whether a calcimimetic or vitamin D analog should be added. This is based upon 
calcium, phosphate, and PTH levels that are measured when administering optimal 
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phosphate binder therapy. The final step is to adjust the doses of phosphate binders, 
active vitamin D, and cinacalcet to attempt to attain target values. There is a variable 
interrelationship between phosphate binders (either calcium or non-calcium containing 
binders), calcitriol or vitamin D analogs and calcimimetics in treatment.  In the end the 
clinician must balance these medications in order successfully treat 
hyperparathyroidism. 
 
The approach to treating hyperphosphatemia in dialysis patients is relatively the same 
as compared to the treatment in the predialysis group.  Nonetheless there are certain 
differences which need to be addressed. In regards to phosphate restriction, protein 
supplementation (which contributes to high phosphate intake) rather than protein 
restriction is the goal. In this setting, the patient should be encouraged to avoid 
unnecessary dietary phosphate while increasing the intake of high-biologic-value 
sources of protein.  The reason for this is that dialysis patients frequently suffer from 
borderline malnutrition.  Restricting dietary protein could affect clinical outcomes by 
further increasing malnutrition.  In regards to phosphate binders treatment principles 
remain the same as those in the predialysis group. Currently there are no randomized 
clinical trials for phosphate binders in this group of patients.  Any excess phosphate can 
be removed with hemodialysis.  Approximately 1000 mg of phosphate can be removed 
in each session.  Patients have the option of extended dialysis or nocturnal dialysis if 
time permits.  Patients receiving nocturnal dialysis removed twice the amount of 
phosphorous per week compared with those on thrice-weekly intermittent dialysis.  A 
randomized controlled clinical trial of 51 patient’s randomly assigned to 6 times weekly 
nocturnal dialysis versus thrice-weekly intermittent dialysis showed significant and 
sustained decreases in serum phosphorus levels over a 6 month period (Walsh et al. 
2010). 
 
The general approach to the use of vitamin D analogs was outlined in the predialysis 
section.  The same principles in approach apply to this group of patients.  Currently 
there have been no randomized controlled clinical trials to assess vitamin D analog 
effects on patient-based outcomes such as fractures and mortality.  Furthermore there 
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is lack of evidence on which vitamin D analog to administer.  Here we will discuss 
evidence on two vitamin D analogs, Calcitriol and Paricalcitol which are available in 
Croatia.  It has been assumed since Paricalcitol has specific actions on target receptors 
(less gut absorption of calcium and phosphate and less increments in serum values of 
calcium and phosphate) there could be a survival advantage.  However, data from the 
only prospective, comparative study suggest no significant differences between 
paricalcitol and calcitriol. In this phase-III, double-blind, multicenter, randomized open-
labeled trial, paricalcitol was directly compared with calcitriol among 263 hemodialysis 
patients with plasma PTH levels >300 pg/mL and a serum Ca x P product <75 (Sprague 
et al. 2003).  To asses effect on mortality, paricalcitol was evaluated in a large cohort 
(the survival of hemodialysis patients administered paricalcitol (29,021 patients) or 
calcitriol (38,378 patients)) (Teng et al. 2003).  The findings showed that at three-year 
follow-up, mortality was significantly lower in the paricalcitol group (crude mortality of 18 
versus 22.3 percent per person-year for paricalcitol and calcitriol) (Teng et al. 2003).  
There are some issues with the studies design, such as randomization.  This study 
should not be considered when selecting between the two vitamin D analogs.  Currently 
both compounds can be used until further randomized controlled clinical trials have 
been performed. 
 
As mentioned previously Cinacalcet is a calcimimetic used often in combination with 
vitamin D and phosphate binders when levels of PTH are excessive.  The indications for 
calcimimetic therapy are the following: indicated in dialysis patients with PTH levels 
>300 pg/mL who have serum calcium levels >8.4 mg/dL (>2.1 mmol/L). 
Hyperphosphatemia is not a contraindication for starting cinacalcet, unlike vitamin D 
analogs.  There are numerous efficacy studies evaluating the effects of Cinacalcet.  In 
one large trial (which was the combination of three phase-III studies), 1136 dialysis 
patients with iPTH levels of >300 pg/mL were randomly assigned to traditional therapy 
plus cinacalcet HCl or placebo for 26 weeks (Moe et al. 2005). Some of the findings 
were as follows:  sufficient control of PTH levels, calcium and phosphorous levels 
compared with placebo (Moe et al. 2005). A combined analysis of the three phase-III 
trials (which are also analyzed in the previously cited study) and one phase-II trial also 
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found that, compared with placebo, cinacalcet lowered the risk of parathyroidectomy, 
fracture, and cardiovascular hospitalization (Cunningham et al. 2005).  Does cinacalcet 
improve all-cause mortality and cardiovascular mortality? In the EVOLVE randomized 
trial, cinacalcet did not decrease the risk of death or major cardiovascular events among 
hemodialysis patients (Chertow et al. 2012).  Cinacalcet reduced the rate of 
parathyroidectomy by approximately half (Chertow et al. 2012).  Furthermore, in a 
recent published meta-analysis of all 9 clinical trials involving cinacalcet, there was no 
reduction in all-cause mortality and cardiovascular mortality (Palmer et al. 2013).  
 
Table 1.  Prevalence of secondary hyperparathyroidism in dialysis patients at 
Department of Nephrology of Klinicki Bolnicki Centar Sestre Milosdrnice, Zagreb 
Croatia.  Different therapy regiments, with serum calcium and phosphate levels are also 
shown. 
 Sex 
(F=Female) 
(M-Male) 
Age PTH 
(pg/mL) 
Ca 
(Calcium) 
(mmol/L) 
P 
(Phosphate) 
(mmol/L) 
Therapy 
1. F 53 253 2.16 1.15 Zemplar-2mcg 3x/week 
Osvaren-3x1g (between meals) 
2. F 54 1162 2.63 1.77 Zemplar-4mcg 3x/week 
Renvela-800mg with meal 3x 
daily 
3. F 78 629 2.16 1.1 Zemplar-2mcg 3x/week 
Osvaren-3x1g (between meals) 
4. F 89 232 2.07 1.23 Renvela-800mg with meal 3x 
daily 
5. F 67 290 2.28 2.85 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
6. F 57 63 2.43 1.11 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal  3x 
daily 
Calcium Carbonate 
7. M 62 76 2.17 0.63 Rocaltrol-0.25mcg 
Renvela- 3x1g with meal 
8. F 55 29 2.51 1.63 Osvaren-3x1g (between meals) 
9. M 82 168 2.26 1.52 Zemplar-2mcg 3x/week 
Osvaren-3x1g (between meals) 
10. M 57 387 2.22 1.01 Rocaltrol-0.25mcg daily 
Calcium Carbonate 
11. F 60 85 2.08 1.46 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal 3x 
daily 
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12. M 76 241 2.41 1.39 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
13. M 62 198 2.34 1.1 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
14. M 81 32 2.51 0.93 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
15. M 74 84 2 0.82 Osvaren-3x1g (between meals) 
16. F 65 669 2.28 1.55 Renvela-800mg with meal 3x 
daily 
17. M 69 780 2.33 1.46 Zemplar-4mcg 3x/week 
Renvela-800mg with meal 3x 
daily 
18. M 68 244 2.17 1.00 Osvaren-3x1g (between meals) 
19. M 66 54 2.21 1.29 Currently no therapy 
20. M 59 320 2.43 1.55 Renvela-2g with meal 3x daily 
Rocaltrol-2.5mcg 3x weekly 
21. F 37 173 2.68 1.31 Renvela-1g with meal 3x daily 
Rocaltrol-0.25mcg daily 
22. F 74 182 2.17 1.12 Calcium carbonate 
Rocaltrol-2.5mcg 3x weekly 
23. M 56 79 2.26 1.4 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
24. F 77 8 2.54 2.55 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.5mcg 3xweekly 
25. M 41 85 2.23 1.68 Rocaltrol-0.25mcg daily 
26. F 86 415 2.47 1.22 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
27. F 80 166 2.15 1.45 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
Zemplar-4mcg 3x/week 
28. M 47 249 2.33 1.64 Rocaltrol-0.25mcg daily 
Renvela-1g with meal 3x daily 
29. F 44 289 2.18 1.98 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
30. F 78 62 2.19 1.03 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
31. M 60 174 2.33 1.04 Renvela-2g with meal 3x daily 
Rocaltrol-0.5 mcg daily 
32. F 79 264 2.5 1.75 Rocaltrol-0.25mcg daily 
Osvaren-3x1g (between meals) 
33. F 77 907 2.27 1.75 Rocaltrol-0.25mcg daily 
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Osvaren-3x1g (between meals) 
34. M 62 598 2.31 1.34 Rocaltrol-0.25mcg daily 
35. F 68 9 2.25 1.03 Zemplar-2mcg 3x/week 
Osvaren-3x1g (between meals) 
36. M 63 433 2.49 2.24 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal 2x 
daily 
37. M 72 190 2.25 2.07 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal 3x 
daily 
38. F 55 194 2.37 2.06 Zemplar-2mcg 3x/week 
Renvela-800mg with meal 3x 
daily 
39. F 45 2027 2.56 1.99 Renvela-1-2g with meal 3x daily 
Zemplar-2mcg 3x/week 
40. F 32 82 2.41 0.83 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
41. M 58 67 2.18 1.5 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
42. M 71 503 2.5 1.15 Renvela-800mg with meal 3x 
daily 
43. F 29 395 2.43 2.86 Renvela-800mg with meal 3x 
daily 
Rocaltrol-0.25mcg daily 
44. M 71 508 2.36 1.14 Renvela-800mg with meal 3x 
daily 
Zemplar-1mcg 3x/week 
45. M 83 239 2.28 0.8 Zemplar-1mcg 3x/week 
46. M 56 120 2.3 1.6 Rocaltrol-0.25mcg daily 
Calcium Carbonate 
47. F 67 246 2.3 0.75 Zemplar-2mcg 3x/week 
Renvela-1-2g with meal 3x daily 
48. M 66 151 2.36 2.52 Rocaltrol-0.25mcg daily 
Renvela-1-2g with meal 3x daily 
49. M 60 160 2.21 1.55 Renvela-800mg with meal 3x 
daily Rocaltrol-0.25mcg daily 
50. M 64 67 2.18 1.5 Rocaltrol-0.25mcg daily 
Renvela-1g with meal 3x daily 
51. F 61 1127 2.03 1.31 Rocaltrol-0.5mcg daily 
Renvela-800mg with meal 3x 
daily 
52. M 72 83 2.23 1.88 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal 3x 
daily 
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53. F 77 264 2.12 1.56 Rocaltrol-0.25mcg daily 
54. F 80 136 2.21 1.26 Zemplar-2mcg 3x/week 
Renvela-800mg with meal 3x 
daily 
55. M 71 17 2.59 1.24 Rocaltrol-0.25mcg daily 
Renvela-800mg with meal 3x 
daily 
56. M 76 192 2.14 1.41 Zemplar-2mcg 3x/week 
Renvela-1-2g with meal 3x daily 
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